| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 722,520 | 814,320 | 784,510 | 724,510 | 695,420 |
| Sales Growth | -11.27% | +3.80% | +8.28% | +4.18% | -4.80% |
| Net Income | 62,260 | 35,080 | 2,370 | 22,420 | 12,200 |
| Net Income Growth | +77.48% | +1,380.17% | -89.43% | +83.77% | +139.25% |
Amneal Pharmaceuticals Inc (AMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States.
Fiscal Year End Date: 12/31